DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2019年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3727

Title: Combination of L-Carnitine and Angiotensin-II type 1 Receptor Blocker has Beneficial Effects on Hepatic Fibrosis in a Non-Alcoholic Steatohepatitis Rat Model.
Other Titles: L-カルニチンとアンギオテンシン-II1型受容体遮断薬の組み合わせは、非アルコール性脂肪肝炎ラットモデルにおける肝線維症に有益な効果を有する
Authors: Kubo, Takuya
Kawaratani, Hideto
Sawada, Yasuhiko
Fujinaga, Yukihisa
Ozutsumi, Takahiro
Kaya, Daisuke
Tsuji, Yuki
Nakanishi, Keisuke
Furukawa, Masanori
Kitagawa, Kou
Saikawa, Soichiro
Sato, Shinya
Takaya, Hiroaki
Kaji, Kosuke
Shimozato, Naotaka
Moriya, Kei
Namisaki, Tadashi
Akahane, Takemi
Mitoro, Akira
Yoshiji, Hitoshi
Keywords: Angiotensin-2 type 1 Receptor Blocker
L-carnitine
Nonalcoholic Steatohepatitis
Hepatic Fibrosis
Oxidative Stress
Issue Date: Dec-2019
Publisher: Biomedical Research Network+
Citation: Biomedical journal of scientific and technical research Vol.23 No.5 p.17787-17792 (2019 Dec)
Abstract: Inflammation and oxidative stress contribute to the progression of nonalcoholic steatohepatitis (NASH). Hepatic fibrosis and activated hepatic stellate cells (Ac-HSCs) are attenuated by Angiotensin-II type 1 Receptor Blocker (ARB), and L-carnitine is effective for NASH by ameliorating oxidative stress, but neither agent is effective in a clinical setting. We evaluated the effect of the combination of L-carnitine and ARB on liver fibrosis using a rat NASH model. A Choline-Deficient/L-Amino Acid-defined (CDAA) diet was fed to F344 rats for 8 weeks. The rats were then divided into a control group, group receiving L-carnitine or ARB alone, and group receiving L-carnitine plus ARB. Therapeutic efficacy was assessed by evaluating liver fibrosis, liver fatty acid metabolism, and oxidative stress. ARB inhibited liver-specific tumor necrotic factor-α and LPS-binding protein, which are involved in hepatic inflammation. L-Carnitine reduced hepatic oxidative stress by rescuing hepatic sterol-regulatory elementbinding protein 1 and thiobarbituric acid reactive substances induced by the CDAA diet. Combination of L-carnitine and ARB improved liver fibrosis, with concomitant HSC suppression. Therefore, we suggest that L-carnitine and ARB are effective in suppressing liver fibrosis. Currently both drugs are in clinical use, and a combination of the two could be an effective therapy for NASH fibrosis.
Description: 博士(医学)・甲第736号・令和2年3月16日
Copyright © 2019 Hideto Kawaratani, Biomed J Sci & Tech Res. This is an openaccess article distributed under the terms of the Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/).
URI: http://hdl.handle.net/10564/3727
ISSN: 25741241
Academic Degrees and number: 24601A736
Degree-granting date: 2020-03-16
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2019年度

Files in This Item:

File Description SizeFormat
01甲736本文の要旨.pdf甲736本文の要旨1.35 MBAdobe PDFView/Open
02甲736審査要旨.pdf甲736審査要旨2.38 MBAdobe PDFView/Open
03甲736本文.pdf甲736本文581.33 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback